LDLixin Dong

Lixin Dong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lixin Dong has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Churong Li

    Department of Oncology, The First People’s Hospital of Changde City, Changde, China

    1 shared publication
  • Haihong Jin

    Department of Gynecology, The First Hospital of Qinhuangdao, Qinhuangdao, China

    1 shared publication
  • Lin Wang

    Department of Oncology, Hainan General Hospital

    1 shared publication
  • Liyan Cao

    Department of Radiation Oncology, The First Hospital of Qinhuangdao, Qinhuangdao, China

    1 shared publication
  • Qingqing Lu

    Department of Oncology, The First People’s Hospital of Changde City, Changde, China

    1 shared publication
  • Xiaofei Mo

    Department of Oncology, The First People’s Hospital of Changde City, Changde, China

    1 shared publication

Latest Publications

  • Open Access

    DeepLRHE: A Deep Convolutional Neural Network Framework to Evaluate the Risk of Lung Cancer Recurrence and Metastasis From Histopathology Images

    by Zhijun Wu, Lin Wang, Churong Li, Yongcong Cai, Yuebin Liang, Xiaofei Mo, Qingqing Lu, Lixin Dong, Yonggang Liu

    It is critical for patients who cannot undergo eradicable surgery to predict the risk of lung cancer recurrence and metastasis; therefore, the physicians can design the appropriate adjuvant therapy plan. However, traditional circulating tumor cell (CTC) detection or next-generation sequencing (NGS)-based methods are usually expensive and time-inefficient, which urge the need for more efficient computational models. In this study, we have established a convolutional neural network (CNN) framework called DeepLRHE to predict the recurrence risk of lung cancer by analyzing histopathological images of patients. The steps for using DeepLRHE include automatic tumor region identification, image normalization, biomarker identification, and sample classification. In practice, we used 110 lung cancer samples downloaded from The Cancer Genome Atlas (TCGA) database to train and validate our CNN model and 101 samples as independent test dataset. The area under the receiver operating characteristic (ROC) curve (AUC) for test dataset was 0.79, suggesting a relatively good prediction performance. Our study demonstrates that the features extracted from histopathological images could be well used to predict lung cancer recurrence after surgical resection and help classify patients who should receive additional adjuvant therapy.


  • Open Access

    DANCR‐mediated microRNA‐665 regulates proliferation and metastasis of cervical cancer through the ERK/SMAD pathway

    by Liyan Cao, Haihong Jin, Yue Zheng, Yu Mao, Zhanzhao Fu, Xin Li, Lixin Dong

    Emerging evidence has indicated that microRNAs (miRNAs) play an important role in cervical cancer (CC). However, the role of miRNA (miR)‐665 in cervical cancer remains unclear. The aim of the present study was to investigate the potential functions of miR‐665 in CC and to identify the underlying mechanisms of action. Herein, we show that miR‐665 was downregulated in CC tissues and cell lines, which is negatively correlated with tumor size, distant metastasis, advanced TNM stage and poor prognosis. Functionally, miR‐665 inhibited cell proliferation, migration and invasion and resistance of cisplatin for CC cells, as well as tumor growth. We validated that transforming growth factor beta receptor 1 (TGFBR1) was a direct target of miR‐665 and mediated the ERK/SMAD pathway. In addition, we identified miR‐665 as the competing endogenous RNA for long noncoding (lnc)‐DANCR. These observations suggested that lnc‐DANCR‐mediated miR‐665 downregulation regulates the malignant phenotype of CC cells by targeting TGFBR1 through the ERK/SMAD pathway, which may present a pathway for novel therapeutic stratagems for CC therapy.